Abstract:Objective To provide reference for the rational antimicrobial use for the clinical treatment of Corynebacterium striatum (C. striatum) infection and prevent its nosocomial transmission. Methods 49 strains of clinica-lly isolated C. striatum from a hospital were collected. Clinical data analysis, antimicrobial susceptibility test of 12 antimicrobial agents and detection of carriage of 7 antimicrobial-resistant genes were performed. Results The specimen sources of the 49 C. striatum strains were mostly sputum (63.27%), followed by urine (16.33%). Patients were mainly distributed in the intensive care unit (36.73%), cadre-special clinics (26.53%) and neurology department (16.33%). The resistance rates of C. striatum to ceftriaxone, erythromycin and ciprofloxacin were all 100%, while the resistance rates to penicillin, clindamycin and meropenem were 95.92%, 95.92% and 93.88%, respectively. The resistance rates to gentamicin and rifampicin were both low, which were 12.24% and 8.16%, respectively. No strains were resistant to linezolid or vancomycin. The positive rates of the ermX gene and tetL gene were both 100%, while the positive rates of tetW gene, aph(3'')-Ib gene and aac(6')-Ib gene were 69.39%, 18.37% and 6.12%, respectively. No strains carrying aadA gene and blaIMP gene were detected. Conclusion C. striatum mainly causes respiratory and urinary tract infections in immunocompromised individuals and elderly patients. Antimicrobial resistance of C. striatum is serious, but the resistance rates to gentamicin, rifampicin, linezolid and vancomycin are low, which can be used for the treatment of infections caused by C. striatum.